Marker Therapeutics(MRKR) - 2024 Q4 - Annual Results

Exhibit 99.1 Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and ef icacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research ...